mRNA-based monkeypox virus vaccine prevents disease in non-human primates
Cell · 2024
DOI: 10.1016/j.cell.2024.02.011 ↗Kurz gefasst
Kommentar in der Zeitschrift Cell, 2024. Verfasst von Adam N Nitido und 1 weiteren Autor:innen. Beteiligte Einrichtung: Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: mRNA Vaccines, Smallpox Vaccine, Viral Vaccines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: NIDA NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
The mpox outbreak in 2022 launched a vaccination campaign employing an existing vaccine with moderate protection, highlighting the lack of scalable Orthopoxvirus vaccines with optimal protection. In this issue of Cell, Zuiani et al. report pre-clinical findings of an mRNA-based mpox vaccine, paving the way for Phase I/II clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: abalazs@mgh.harvard.edu.
Förderung
- NIDA NIH HHS
- NIAID NIH HHS
Zitieren
APA
Nitido, A. N., & Balazs, A. B. (2024). mRNA-based monkeypox virus vaccine prevents disease in non-human primates. Cell. https://doi.org/10.1016/j.cell.2024.02.011
Vancouver
Nitido AN, Balazs AB. mRNA-based monkeypox virus vaccine prevents disease in non-human primates. Cell. 2024. doi:10.1016/j.cell.2024.02.011
BibTeX
@article{Nitido2024,
author = {Nitido, Adam N and Balazs, Alejandro B},
title = {mRNA-based monkeypox virus vaccine prevents disease in non-human primates},
journal = {Cell},
year = {2024},
doi = {10.1016/j.cell.2024.02.011}
}
EUVIMED